Kymera Therapeutics vs Protagonist Therapeutics
Protagonist Therapeutics reported revenue of $46 million in fiscal 2025, 1.2 times Kymera Therapeutics' $39 million in fiscal 2025. Kymera Therapeutics' revenue fell 16.7% in its latest year, and Protagonist Therapeutics' fell 89.4%. Kymera Therapeutics had an operating margin of -891.1%, against -343.6% at Protagonist Therapeutics. Free cash flow was −$234 million at Kymera Therapeutics and $56 million at Protagonist Therapeutics.
Side by side
| Kymera Therapeutics | Protagonist Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $39M | $46M |
| Revenue growth | −16.7% | −89.4% |
| Revenue growth a year, last 5 years | 2.9% | 10.0% |
| Gross margin | 0.0% | — |
| Operating margin | −891.1% | −343.6% |
| Net margin | −794.0% | −282.8% |
| Free cash flow | −$234M | $56M |
| Free cash flow margin | −597.6% | 121.9% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 12.6% | −2.3% |
| Last close | $127.57 | $130.95 |
| P/E at the last close | — | 27.8× |
| Insider trades, last 12 months | bought $172.5 million, sold $461.2 million | sold $79.4 million |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Kymera TherapeuticsProtagonist Therapeutics
Operating margin
Percent of revenue
Kymera TherapeuticsProtagonist Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Kymera TherapeuticsProtagonist Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Kymera Therapeutics and Protagonist Therapeutics pages.